Brokerages Set NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Target Price at $47.00

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have received a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $46.5455.

A number of equities analysts have issued reports on NAMS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Needham & Company LLC increased their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Leerink Partners reaffirmed an “outperform” rating and set a $55.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. HC Wainwright raised NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. Finally, Stifel Nicolaus boosted their target price on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th.

NewAmsterdam Pharma Stock Down 2.1%

NewAmsterdam Pharma stock opened at $34.28 on Tuesday. The business’s 50-day simple moving average is $34.05 and its 200 day simple moving average is $32.88. The stock has a market cap of $3.89 billion, a price-to-earnings ratio of -19.81 and a beta of 0.06. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. As a group, sell-side analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 45,481 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $35.31, for a total value of $1,605,934.11. Following the completion of the sale, the insider owned 53,500 shares of the company’s stock, valued at approximately $1,889,085. This represents a 45.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $36.21, for a total transaction of $2,719,986.57. Following the transaction, the chief accounting officer directly owned 15,000 shares in the company, valued at approximately $543,150. This represents a 83.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 650,421 shares of company stock worth $22,417,631. 20.84% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Atle Fund Management AB boosted its position in NewAmsterdam Pharma by 23.2% during the third quarter. Atle Fund Management AB now owns 193,625 shares of the company’s stock valued at $5,507,000 after purchasing an additional 36,402 shares during the last quarter. Jennison Associates LLC increased its position in shares of NewAmsterdam Pharma by 42.5% during the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after purchasing an additional 1,252,451 shares during the last quarter. Keybank National Association OH bought a new stake in shares of NewAmsterdam Pharma during the 3rd quarter worth approximately $455,000. Franklin Resources Inc. raised its stake in shares of NewAmsterdam Pharma by 30.6% during the 2nd quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock worth $6,053,000 after purchasing an additional 78,300 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. boosted its holdings in shares of NewAmsterdam Pharma by 3.0% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock valued at $300,754,000 after buying an additional 490,656 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.